Access Denied? The Unintended Consequences of Pending Drug Pricing Rules.

PMPRB access clinical trials development funding oncology outcomes pharmacotherapy research

Journal

Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503

Informations de publication

Date de publication:
02 04 2022
Historique:
received: 02 03 2022
revised: 28 03 2022
accepted: 31 03 2022
entrez: 21 4 2022
pubmed: 22 4 2022
medline: 26 4 2022
Statut: epublish

Résumé

The government of Canada now plans to bring into force new federal drug pricing regulations on 1 July 2022. We do not take issue with the goal of medication affordability, which is vital in healthcare the world over. Our concern is that the new guidelines are being implemented without due consideration for three major unintended consequences: regulatory changes will lower the number of clinical trials for new medications in Canada, fewer clinical trials will mean lower research and development investments, and changes will reduce patients' access to new medications. Access to effective medications is a cornerstone of healthcare for Canadian patients. As physicians, our duty to patient care demands that we tell the government to protect the right of Canadians to timely access to life-changing medicines.

Identifiants

pubmed: 35448178
pii: curroncol29040204
doi: 10.3390/curroncol29040204
pmc: PMC9025245
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2504-2508

Références

Curr Oncol. 2016 Oct;23(5):e454-e460
pubmed: 27803605
Oncologist. 2020 Jan;25(1):e130-e137
pubmed: 31506392
Eur J Health Econ. 2020 Feb;21(1):129-151
pubmed: 31583483

Auteurs

Alan Kaplan (A)

Enhanced Care Clinic, Aurora, ON L4G 1N2, Canada.

David J Stewart (DJ)

Division of Medical Oncology, The Ottawa Hospital, University of Ottawa, Ottawa, ON K1Y 4E9, Canada.

Gerald Batist (G)

Segal Cancer Centre, Jewish General Hospital, Montreal, QC H3T 1E2, Canada.

Silvana Spadafora (S)

Algoma District Cancer Program, Sault Ste. Marie, ON P6B 0A8, Canada.

Sandeep Sehdev (S)

Division of Medical Oncology, The Ottawa Hospital, University of Ottawa, Ottawa, ON K1Y 4E9, Canada.

Shaun G Goodman (SG)

St. Michael's Hospital, Department of Medicine, University of Toronto, Toronto, ON M5S 1A1, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH